{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T14:34:55Z","timestamp":1781706895802,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Xinjiang Uygur Autonomous Region Regional Collaborative Innovation Project","award":["2020E0270"],"award-info":[{"award-number":["2020E0270"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The molecular landscapes of diffuse large B-cell lymphoma (DLBCL) remained to be comprehensively investigated with an urgent need to identify novel prognostic biomarkers guiding prognostic stratification and disease monitoring. Baseline tumor samples of 148 DLBCL patients were analyzed using targeted next-generation sequencing (NGS) for mutational profiling, whose clinical reports were retrospectively reviewed. In this cohort, the subgroup of old DLBCL patients (age at diagnosis\u2009&gt;\u200960,<jats:italic>N<\/jats:italic>\u2009=\u200980) exhibited significantly higher Eastern Cooperative Oncology Group scores and International Prognostic Index than their young counterparts (age at diagnosis\u2009\u2264\u200960,<jats:italic>N<\/jats:italic>\u2009=\u200968). As revealed by the NGS results,<jats:italic>PIM1<\/jats:italic>(43.9%),<jats:italic>KMT2D<\/jats:italic>(31.8%),<jats:italic>MYD88<\/jats:italic>(29.7%), and<jats:italic>CD79B<\/jats:italic>(27.0%) were identified as the most frequently mutated genes. Aberrations of genes of the immune escape pathway were significantly enriched in the young subgroup, while the altered epigenetic regulators were more abundant in the old patients.<jats:italic>FAT4<\/jats:italic>mutation was identified as a positive prognostic biomarker, associated with longer progression-free survival and overall survival in the entire cohort and the old subgroup, using the Cox regression analyses. However, the prognostic function of<jats:italic>FAT4<\/jats:italic>was not reproduced in the young subgroup. We comprehensively analyzed the pathological and molecular characteristics of old and young DLBCL patients and demonstrated the prognostic value of<jats:italic>FAT4<\/jats:italic>mutation, which requires further validation with sizable cohorts in future research.<\/jats:p>","DOI":"10.1007\/s10238-023-01018-z","type":"journal-article","created":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T15:04:10Z","timestamp":1677078250000},"page":"2675-2685","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Identification of FAT4 as a positive prognostic biomarker in DLBCL by comprehensive genomic analysis"],"prefix":"10.1007","volume":"23","author":[{"given":"Liyang","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuling","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaguli","family":"Abulaiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiping","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Kou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhebaier","family":"Abuduer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsheng","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zailinuer","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuxiang","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengsheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,22]]},"reference":[{"key":"1018_CR1","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.3390\/cancers12071869","volume":"12","author":"AG Solimando","year":"2020","unstructured":"Solimando AG, Annese T, Tamma R, et al. New insights into diffuse large B-cell lymphoma pathobiology. Cancers (Basel). 2020;12:1869.","journal-title":"Cancers (Basel)"},{"key":"1018_CR2","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/ajh.26151","volume":"96","author":"S Susanibar-Adaniya","year":"2021","unstructured":"Susanibar-Adaniya S, Barta SK. 2021 Update on Diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management. Am J Hematol. 2021;96:617\u201329.","journal-title":"Am J Hematol"},{"key":"1018_CR3","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/onco.13610","volume":"26","author":"M Di","year":"2021","unstructured":"Di M, Huntington SF, Olszewski AJ. Challenges and opportunities in the management of diffuse large B-cell lymphoma in older patients. Oncologist. 2021;26:120\u201332.","journal-title":"Oncologist"},{"key":"1018_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.842439","volume":"13","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Fu D, Shi Q, et al. Oncogenic mutations and tumor microenvironment alterations of older patients with diffuse large B-cell lymphoma. Front Immunol. 2022;13: 842439.","journal-title":"Front Immunol"},{"key":"1018_CR5","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/ng.892","volume":"43","author":"L Pasqualucci","year":"2011","unstructured":"Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011;43:830\u20137.","journal-title":"Nat Genet"},{"issue":"481\u2013494","key":"1018_CR6","volume":"171","author":"A Reddy","year":"2017","unstructured":"Reddy A, Zhang J, Davis NS, et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2017;171(481\u2013494): e415.","journal-title":"Cell"},{"key":"1018_CR7","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1073\/pnas.1121343109","volume":"109","author":"JG Lohr","year":"2012","unstructured":"Lohr JG, Stojanov P, Lawrence MS, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A. 2012;109:3879\u201384.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1018_CR8","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1073\/pnas.1205299110","volume":"110","author":"J Zhang","year":"2013","unstructured":"Zhang J, Grubor V, Love CL, et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A. 2013;110:1398\u2013403.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1018_CR9","first-page":"83","volume":"102","author":"E Sabattini","year":"2010","unstructured":"Sabattini E, Bacci F, Sagramoso C, Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010;102:83\u20137.","journal-title":"Pathologica"},{"key":"1018_CR10","doi-asserted-by":"crossref","unstructured":"International Non-Hodgkin's Lymphoma Prognostic Factors P. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987\u2013994.","DOI":"10.1056\/NEJM199309303291402"},{"key":"1018_CR11","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275\u201382.","journal-title":"Blood"},{"key":"1018_CR12","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375\u201390.","journal-title":"Blood"},{"key":"1018_CR13","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.","journal-title":"J Clin Oncol"},{"key":"1018_CR14","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.3324\/haematol.2021.279908","volume":"107","author":"X Wang","year":"2022","unstructured":"Wang X, Su W, Gao Y, et al. A pilot study of the use of dynamic analysis of cell-free DNA from aqueous humor and vitreous fluid for the diagnosis and treatment monitoring of vitreoretinal lymphomas. Haematologica. 2022;107:2154\u201362.","journal-title":"Haematologica"},{"key":"1018_CR15","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41598-017-00520-1","volume":"7","author":"Y Shu","year":"2017","unstructured":"Shu Y, Wu X, Tong X, et al. Circulating tumor DNA mutation profiling by targeted next generation sequencing provides guidance for personalized treatments in multiple cancer types. Sci Rep. 2017;7:583.","journal-title":"Sci Rep"},{"key":"1018_CR16","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-17-2310","volume":"24","author":"Z Yang","year":"2018","unstructured":"Yang Z, Yang N, Ou Q, et al. Investigating novel resistance mechanisms to third-generation EGFR Tyrosine Kinase inhibitor osimertinib in non-small cell lung cancer patients. Clin Cancer Res. 2018;24:3097\u2013107.","journal-title":"Clin Cancer Res"},{"key":"1018_CR17","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378:1396\u2013407.","journal-title":"N Engl J Med"},{"key":"1018_CR18","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/s41571-019-0225-1","volume":"16","author":"Y Miao","year":"2019","unstructured":"Miao Y, Medeiros LJ, Li Y, et al. Genetic alterations and their clinical implications in DLBCL. Nat Rev Clin Oncol. 2019;16:634\u201352.","journal-title":"Nat Rev Clin Oncol"},{"key":"1018_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.677650","volume":"12","author":"F Gao","year":"2021","unstructured":"Gao F, Tian L, Shi H, et al. Genetic landscape of relapsed and refractory diffuse large B-cell lymphoma: a systemic review and association analysis with next-generation sequencing. Front Genet. 2021;12: 677650.","journal-title":"Front Genet"},{"key":"1018_CR20","doi-asserted-by":"publisher","first-page":"4503","DOI":"10.1182\/blood-2009-06-225839","volume":"114","author":"A Mottok","year":"2009","unstructured":"Mottok A, Renne C, Seifert M, et al. Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities. Blood. 2009;114:4503\u20136.","journal-title":"Blood"},{"key":"1018_CR21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.18632\/oncotarget.774","volume":"4","author":"B Schif","year":"2013","unstructured":"Schif B, Lennerz JK, Kohler CW, et al. SOCS1 mutation subtypes predict divergent outcomes in diffuse large B-Cell lymphoma (DLBCL) patients. Oncotarget. 2013;4:35\u201347.","journal-title":"Oncotarget"},{"key":"1018_CR22","doi-asserted-by":"publisher","first-page":"274","DOI":"10.2174\/1568009620666210106122750","volume":"21","author":"Y Isshiki","year":"2021","unstructured":"Isshiki Y, Melnick A. Epigenetic mechanisms of therapy resistance in diffuse large B cell lymphoma (DLBCL). Curr Cancer Drug Targets. 2021;21:274\u201382.","journal-title":"Curr Cancer Drug Targets"},{"key":"1018_CR23","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/MOH.0000000000000249","volume":"23","author":"Y Jiang","year":"2016","unstructured":"Jiang Y, Dominguez PM, Melnick AM. The many layers of epigenetic dysfunction in B-cell lymphomas. Curr Opin Hematol. 2016;23:377\u201384.","journal-title":"Curr Opin Hematol"},{"key":"1018_CR24","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.3324\/haematol.2018.214056","volume":"105","author":"S Ferrero","year":"2020","unstructured":"Ferrero S, Rossi D, Rinaldi A, et al. KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. Haematologica. 2020;105:1604\u201312.","journal-title":"Haematologica"},{"key":"1018_CR25","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13045-017-0438-7","volume":"10","author":"D Juskevicius","year":"2017","unstructured":"Juskevicius D, Jucker D, Klingbiel D, et al. Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38\/07 prospective clinical trial cohort. J Hematol Oncol. 2017;10:70.","journal-title":"J Hematol Oncol"},{"key":"1018_CR26","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.3324\/haematol.2017.184192","volume":"103","author":"M de Charette","year":"2018","unstructured":"de Charette M, Houot R. Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy. Haematologica. 2018;103:1256\u201368.","journal-title":"Haematologica"},{"key":"1018_CR27","doi-asserted-by":"publisher","first-page":"e2104504118","DOI":"10.1073\/pnas.2104504118","volume":"118","author":"M Fangazio","year":"2021","unstructured":"Fangazio M, Ladewig E, Gomez K, et al. Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2021;118:e2104504118.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1018_CR28","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrc3774","volume":"14","author":"DW Scott","year":"2014","unstructured":"Scott DW, Gascoyne RD. The tumour microenvironment in B cell lymphomas. Nat Rev Cancer. 2014;14:517\u201334.","journal-title":"Nat Rev Cancer"},{"key":"1018_CR29","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1186\/s13059-014-0459-2","volume":"15","author":"Y Jiang","year":"2014","unstructured":"Jiang Y, Redmond D, Nie K, et al. Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas. Genome Biol. 2014;15:432.","journal-title":"Genome Biol"},{"key":"1018_CR30","doi-asserted-by":"publisher","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","volume":"120","author":"ZY Xu-Monette","year":"2012","unstructured":"Xu-Monette ZY, Wu L, Visco C, et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2012;120:3986\u201396.","journal-title":"Blood"},{"key":"1018_CR31","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1002\/ijc.33049","volume":"147","author":"S Jiang","year":"2020","unstructured":"Jiang S, Qin Y, Jiang H, et al. Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup. Int J Cancer. 2020;147:2611\u201320.","journal-title":"Int J Cancer"},{"key":"1018_CR32","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/leu.2017.251","volume":"32","author":"K Karube","year":"2018","unstructured":"Karube K, Enjuanes A, Dlouhy I, et al. Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets. Leukemia. 2018;32:675\u201384.","journal-title":"Leukemia"},{"key":"1018_CR33","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/bjc.2015.367","volume":"113","author":"J Cai","year":"2015","unstructured":"Cai J, Feng D, Hu L, et al. FAT4 functions as a tumour suppressor in gastric cancer by modulating Wnt\/beta-catenin signalling. Br J Cancer. 2015;113:1720\u20139.","journal-title":"Br J Cancer"},{"key":"1018_CR34","doi-asserted-by":"publisher","first-page":"9999","DOI":"10.2147\/OTT.S216289","volume":"12","author":"Y Hu","year":"2019","unstructured":"Hu Y, Chen W, Wang J. Mutations in thirty hotspot genes in newly diagnosed chinese multiple myeloma patients. Onco Targets Ther. 2019;12:9999\u201310010.","journal-title":"Onco Targets Ther"},{"key":"1018_CR35","first-page":"2784","volume":"11","author":"X Che","year":"2019","unstructured":"Che X, Jian F, Jia N, et al. FAT4-USP51 complex regulates the proliferation and invasion of endometrial cancer via Hippo pathway. Am J Transl Res. 2019;11:2784\u2013800.","journal-title":"Am J Transl Res"},{"key":"1018_CR36","first-page":"183","volume":"24","author":"AA Abuderman","year":"2020","unstructured":"Abuderman AA, Harb OA, Gertallah LM. Prognostic and clinic-pathological significances of HOXB8, ILK and FAT4 expression in colorectal cancer. Contemp Oncol (Pozn). 2020;24:183\u201392.","journal-title":"Contemp Oncol (Pozn)"},{"key":"1018_CR37","doi-asserted-by":"publisher","first-page":"5137","DOI":"10.18632\/oncotarget.23702","volume":"9","author":"X Jiang","year":"2018","unstructured":"Jiang X, Liu Z, Xia Y, et al. Low FAT4 expression is associated with a poor prognosis in gastric cancer patients. Oncotarget. 2018;9:5137\u201354.","journal-title":"Oncotarget"},{"key":"1018_CR38","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1186\/s12885-021-08108-9","volume":"21","author":"Y Zhuang","year":"2021","unstructured":"Zhuang Y, Wang H, Jiang D, et al. Multi gene mutation signatures in colorectal cancer patients: predict for the diagnosis, pathological classification, staging and prognosis. BMC Cancer. 2021;21:380.","journal-title":"BMC Cancer"},{"key":"1018_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0251272","volume":"16","author":"Y Takashima","year":"2021","unstructured":"Takashima Y, Kawaguchi A, Fukai J, et al. Survival prediction based on the gene expression associated with cancer morphology and microenvironment in primary central nervous system lymphoma. PLoS ONE. 2021;16: e0251272.","journal-title":"PLoS ONE"},{"key":"1018_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.622648","volume":"11","author":"P Li","year":"2021","unstructured":"Li P, Chai J, Chen Z, et al. Genomic mutation profile of primary gastrointestinal diffuse large B-cell lymphoma. Front Oncol. 2021;11: 622648.","journal-title":"Front Oncol"},{"key":"1018_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083244","volume":"8","author":"M Parry","year":"2013","unstructured":"Parry M, Rose-Zerilli MJ, Gibson J, et al. Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma. PLoS ONE. 2013;8: e83244.","journal-title":"PLoS ONE"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01018-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-023-01018-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01018-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T22:24:04Z","timestamp":1728944644000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-023-01018-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,22]]},"references-count":41,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["1018"],"URL":"https:\/\/doi.org\/10.1007\/s10238-023-01018-z","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,22]]},"assertion":[{"value":"21 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yutong Ma, Qiping Shi, Qiuxiang Ou, Yang Shao are employees of Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, China. The other authors declare no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of People\u2019s Hospital of Xinjiang Uygur Autonomous Region (No. KY2019101001). Written informed consent was collected from each patient prior to sample collection.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patients for publication of this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}